The spurious advance of antipsychotic drug therapy

The Lancet

Volumn 373, Issue 9657, 2009, Pages 4-5

  Tyrer, Peter ^a   Kendall, Tim ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b National Collaborating Centre for Mental Health   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; HALOPERIDOL; NEUROLEPTIC AGENT;

ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG POTENCY; HUMAN; PARKINSONISM; PRIORITY JOURNAL; RISK ASSESSMENT; SCHIZOPHRENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 58049189253     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61765-1     Document Type: Note

References (14)

1. Leucht S., Corves C., Arbter D., Engel R.R., Li C., and Davis J.M. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet (2008) 10.1016/S0140-6736(08)61764-X published online Dec 5
2. Janssen P.A., Niemegeers C.J., Awouters F., Schellekens K.H., Megens A.A., and Meert T.F. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties. J Pharmacol Exp Ther 244 (1988) 685-693
3. Lieberman J.A., Stroup S., McEvoy J.P., et al., for the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 353 (2005) 1209-1223
4. Jones P.B., Barnes T.R., Davies L., et al. Randomized controlled trial of effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 63 (2006) 1079-1087
5. Keefe R.S., Bilder R.M., Davis S.M., et al., for the CATIE Investigators and the Neurocognitive Working Group. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 64 (2007) 633-647
6. Rosenheck R.A., Leslie D., Sindelar J., et al., for the CATIE Study Investigators. Cost-effectiveness of second generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 163 (2006) 2080-2089
7. Davies L.M., Lewis S., Jones P.B., et al., on behalf of the CUtLASS team. Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 191 (2007) 14-22
8. Lewis S., and Lieberman J. CATIE and CUtLASS: can we handle the truth?. Br J Psychiatry 192 (2008) 161-163
9. Vedantam S. In antipsychotics, newer isn't better. Washington Post (Washington) Oct 3, 2006. http://www.washingtonpost.com/wp-dyn/content/article/2006/10/02/AR2006100201378.html (accessed Sept 8, 2008).
10. Geddes J., Freemantle N., Harrison P., and Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321 (2000) 1371-1376
11. Turner E.H., Matthews A.M., Linardatos E., Tell T.A., and Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. N Engl J Med 358 (2008) 252-260
12. Whittington C.J., Kendall T., Fonagy P., Cottrell D., Cotgrove A., and Boddington E. Selective serotonin reuptake inhibitors in childhood depression: systematic review of published versus unpublished data. Lancet 363 (2004) 1341-1345
13. Tungeraza T., and Poole R. Influence of drug company authorship and sponsorship on drug trial outcomes. Br J Psychiatry 191 (2007) 82-83
14. Kane J., Honigfeld G., Singer J., and Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45 (1988) 789-796